{
  "objective": {
    "answer": "The primary objective of the paper is to present Assay2Mol, a large language model-based workflow that utilizes existing biochemical screening assays for early-stage drug discovery by generating candidate molecules using in-context learning.",
    "evidence": "We present Assay2Mol, a large language model-based workflow that can capitalize on the vast existing biochemical screening assays for early-stage drug discovery."
  },
  "knowledge_gap": {
    "answer": "The paper addresses the gap in utilizing unstructured text from BioAssay records for drug discovery, which has been untapped due to its format.",
    "evidence": "Unstructured text that describes the biological mechanisms through which these targets operate, experimental screening protocols, and other attributes of assays offer rich information for new drug discovery campaigns but has been untapped because of that unstructured format."
  },
  "novelty": {
    "answer": [
      "Assay2Mol does not require protein structures or sequences, unlike traditional structure-based drug discovery methods.",
      "Assay2Mol generates chemically plausible and synthetically accessible molecules by relying on LLMs pretrained on chemical data.",
      "The workflow retrieves relevant PubChem BioAssay data and uses in-context learning to generate new candidate molecules."
    ],
    "evidence": [
      "Unlike structure-based drug discovery (SBDD) methods, Assay2Mol does not require protein structures or even sequences.",
      "Because Assay2Mol relies on LLMs that are pretrained on chemical data for its molecule generation, the output molecules can be more like 'retrieval' rather than de novo 'generation'.",
      "We introduce Assay2Mol, an LLM-based drug design workflow that retrieves relevant PubChem BioAssay data for a given query and then learns to generate new candidate molecules from this assay context."
    ]
  },
  "inspirational_papers": {
    "answer": "- Kim et al. (2024) PubChem now contains 1.77 million assay records (BioAssay records) comprising ∼300 million bioactivity outcomes across ∼250,000 protein targets and 1,000s of cell lines. (Experimental baselines)\n- Mendez et al. (2018) ChEMBL: towards direct deposition of bioassay data. (Experimental baselines)",
    "evidence": "Public screening data repositories like PubChem (Kim et al., 2024) and ChEMBL (Mendez et al., 2018) possess great value in this regard."
  },
  "method": {
    "steps": [
      {
        "step": "Retrieve relevant BioAssays based on protein target descriptions.",
        "input": "Protein target descriptions, phenotypic data, or other textual information.",
        "output": "Relevant BioAssays retrieved from PubChem.",
        "evidence": "Given input such as protein target descriptions, phenotypic data, or other textual information, Assay2Mol retrieves relevant BioAssays."
      },
      {
        "step": "Summarize BioAssays and retrieve experimental tables.",
        "input": "BioAssay IDs from retrieved BioAssays.",
        "output": "Summarized BioAssays and experimental tables.",
        "evidence": "The BioAssay ID is then used to retrieve experimental tables."
      },
      {
        "step": "Generate candidate molecules using in-context learning.",
        "input": "Protein description, BioAssay summaries, and data tables.",
        "output": "Generated candidate molecules.",
        "evidence": "The final molecule generation prompt is formed by combining the description, summarization, and selected test molecules with associated test outcomes, enabling the LLM to generate relevant active molecules."
      }
    ],
    "tools": [
      {
        "name": "OpenAI text embedding tool",
        "description": "Used to obtain embeddings for protein descriptions and BioAssay records.",
        "evidence": "We use the OpenAI text embedding tool (Neelakantan et al., 2022) and obtain an embedding for BioAssay record i in json format."
      },
      {
        "name": "AutoDock Vina",
        "description": "Used to score the binding complementarity of generated molecules with protein targets.",
        "evidence": "The average AutoDock Vina (Eberhardt et al., 2021) score for the five molecules without BioAssay context is -7.44."
      }
    ],
    "benchmark_datasets": [
      {
        "name": "CrossDocked2020",
        "data_description": "A dataset for structure-based drug design containing docked protein binding complexes.",
        "usage": "Used to assess how BioAssay context compares to protein structure context for generating candidate protein binders.",
        "evidence": "CrossDocked2020 (CrossDocked for short) is a common dataset for SBDD (Francoeur et al., 2020) that allows us to assess how BioAssay context compares to protein structure context for generating candidate protein binders."
      }
    ],
    "evaluation_metrics": [
      {
        "name": "Vina Dock",
        "purpose": "Measures the binding complementarity of a molecule with a protein target.",
        "application": "Used to score the generated molecules' interaction strength with protein targets.",
        "evidence": "We use Vina Dock to score the binding complementarity of a molecule, or the strength of interaction, with a protein target."
      },
      {
        "name": "Qualitative Estimate of Drug-Likeness (QED)",
        "purpose": "Measures the drug-likeness of generated molecules.",
        "application": "Used to evaluate the drug-likeness of generated molecules.",
        "evidence": "Qualitative Estimate of Drug-Likeness (QED) and Synthetic Accessibility (SA) are computed with RDKit (Landrum, 2016)."
      }
    ]
  },
  "method_type": {
    "methods": [
      {
        "name": "Literature or Dataset Retrieval",
        "description": "The system retrieves relevant BioAssays based on protein target descriptions.",
        "evidence": "Given input such as protein target descriptions, phenotypic data, or other textual information, Assay2Mol retrieves relevant BioAssays."
      },
      {
        "name": "Knowledge Extraction and Structurization",
        "description": "The system summarizes BioAssays and retrieves experimental tables.",
        "evidence": "The BioAssay ID is then used to retrieve experimental tables."
      },
      {
        "name": "Hypothesis or Idea Generation",
        "description": "The system generates candidate molecules using in-context learning.",
        "evidence": "The final molecule generation prompt is formed by combining the description, summarization, and selected test molecules with associated test outcomes, enabling the LLM to generate relevant active molecules."
      }
    ]
  },
  "subject_area": {
    "areas": [
      {
        "name": "Health Sciences",
        "description": "The paper focuses on drug discovery using biochemical screening assays.",
        "evidence": "In biochemistry, molecule screening assays evaluate the functional responses of candidate molecules against disease targets."
      },
      {
        "name": "Applied Sciences & Engineering",
        "description": "The paper develops a workflow for drug design using large language models.",
        "evidence": "We present Assay2Mol, a large language model-based workflow that can capitalize on the vast existing biochemical screening assays for early-stage drug discovery."
      }
    ]
  },
  "performance_summary": {
    "performance_summary": [
      {
        "summary": "Assay2Mol consistently outperforms the best SBDD method, TargetDiff, in average docking scores.",
        "evidence": "All versions of Assay2Mol consistently outperform the best SBDD method, TargetDiff, in average docking scores (Table 1)."
      }
    ],
    "baselines": [
      {
        "name": "TargetDiff",
        "description": "A structure-based drug design method used for comparison.",
        "evidence": "We compare Assay2Mol against the following SBDD methods: CVAE (Ragoza et al., 2022), AR (Luo et al., 2022), Pocket2Mol (Peng et al., 2022), GraphBP (Liu et al., 2022), TamGen (Wu et al., 2024) and TargetDiff (Guan et al., 2023)."
      }
    ],
    "benchmark_datasets": [
      {
        "name": "CrossDocked2020",
        "data_description": "A dataset for structure-based drug design containing docked protein binding complexes.",
        "usage": "Used to assess how BioAssay context compares to protein structure context for generating candidate protein binders.",
        "evidence": "CrossDocked2020 (CrossDocked for short) is a common dataset for SBDD (Francoeur et al., 2020) that allows us to assess how BioAssay context compares to protein structure context for generating candidate protein binders."
      }
    ],
    "evaluation_metrics": [
      {
        "name": "Vina Dock",
        "purpose": "Measures the binding complementarity of a molecule with a protein target.",
        "application": "Used to score the generated molecules' interaction strength with protein targets.",
        "evidence": "We use Vina Dock to score the binding complementarity of a molecule, or the strength of interaction, with a protein target."
      },
      {
        "name": "Qualitative Estimate of Drug-Likeness (QED)",
        "purpose": "Measures the drug-likeness of generated molecules.",
        "application": "Used to evaluate the drug-likeness of generated molecules.",
        "evidence": "Qualitative Estimate of Drug-Likeness (QED) and Synthetic Accessibility (SA) are computed with RDKit (Landrum, 2016)."
      }
    ]
  },
  "benchmark_dataset": {
    "name": "CrossDocked2020",
    "data_description": "A dataset for structure-based drug design containing docked protein binding complexes.",
    "usage": "Used to assess how BioAssay context compares to protein structure context for generating candidate protein binders.",
    "evidence": "CrossDocked2020 (CrossDocked for short) is a common dataset for SBDD (Francoeur et al., 2020) that allows us to assess how BioAssay context compares to protein structure context for generating candidate protein binders."
  },
  "limitations": {
    "limitations": [
      {
        "name": "Relevance Assessment Imperfection",
        "description": "The LLM's assessment of BioAssay relevance is imperfect, leading to potential inclusion of irrelevant BioAssays.",
        "evidence": "Having LLMs directly assess the relevance of the retrieved BioAssay text guards against many irrelevant matches but is imperfect (Table 4)."
      },
      {
        "name": "Conditional Text Query Limitation",
        "description": "The current version of Assay2Mol cannot properly process conditional text queries, such as molecules that inhibit proteins A, B, and C but not D and E.",
        "evidence": "A related limitation is that the current version of Assay2Mol cannot properly process conditional text queries, such as molecules that inhibit proteins A, B, and C but not D and E."
      }
    ]
  },
  "future_directions": {
    "future_directions": [
      {
        "name": "Enhance BioAssay Retrieval",
        "description": "Improve the initial embedding-based query and BioAssay similarity calculations to better capture the complexity of biological regulation in pathways.",
        "evidence": "For example, we observed that the initial embedding-based query and BioAssay similarity calculations are not sophisticated enough to capture the complexity of biological regulation in pathways (Appendix A.6)."
      },
      {
        "name": "Improve LLM Interpretation",
        "description": "Explore methods to enhance LLM interpretation of the desired activity of generated molecules with respect to target function.",
        "evidence": "We continue to explore methods to enhance LLM interpretation of the desired activity of generated molecules with respect to target function (i.e., activation, inhibition, allosteric regulation)."
      }
    ]
  },
  "resource_link": {
    "answer": "https://github.com/gitter-lab/Assay2Mol",
    "evidence": "The code is available at https://github.com/gitter-lab/Assay2Mol under the MIT License."
  }
}